Inactive Instrument
Checkmate Pharmaceuticals, Inc. Stock
Stocks
CMPI
US1628181083
Biotechnology & Medical Research
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 62 | 2018-12-11 | |
Robert Landry
DFI | Director of Finance/CFO | 62 | 2022-05-30 |
Chris French
CTO | Chief Tech/Sci/R&D Officer | - | 2016-06-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Nouhad Husseini
BRD | Director/Board Member | - | 2022-05-30 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 5/31/22 | Issuer sale | Director | 36,778 | 0.1700% | ||
| 5/31/22 | Issuer sale | Chief Financial Officer | 278,480 | 1.2874% | ||
| 5/31/22 | Issuer sale | Chief Executive Officer | 279,437 | 1.2919% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | +0.38% | - | - | 231M | |
| -2.01% | -7.86% | +54.60% | +70.97% | 70.44B | |
| +3.84% | -11.02% | +8.59% | +58.77% | 50.31B | |
| +3.35% | +1.42% | +11.85% | +37.39% | 47.51B | |
| +0.61% | +1.64% | +28.13% | +31.85% | 42.91B | |
| +2.87% | -3.57% | +307.79% | +467.70% | 40.39B | |
| +0.66% | -3.16% | +9.84% | +102.66% | 39.69B | |
| +0.06% | -1.43% | +10.47% | +43.27% | 30.59B | |
| -2.95% | -14.09% | +37.94% | +1.30% | 26.8B | |
| -0.24% | -6.39% | -13.10% | -8.05% | 22.36B | |
| Average | +0.62% | -5.58% | +50.68% | +89.54% | 41.22B | |
| Weighted average by Cap. | +0.80% | -5.44% | +53.67% | +94.99% |
Employees
31
